Increasing demand for antibodies in therapeutic applications is fostering the growth of the antibodies market
Antibodies
also referred to as immunoglobulin, are basically a large, polysaccharide
Y-shape protein that is used by your body to identify and destroy foreign
objects like viruses and pathogens. The antibody recognizes an external
molecule of the pathogen, known as antigens. The antibodies release substances
into the lymphatic fluid where they interact with the infected cells. These
release substances to assist in destroying the infected cells and preventing
infection from recurring.
The
growing demand for antibodies in therapeutic applications is propelling the
growth of the antibodies market. The increasing economic burden of cancers and
other chronic diseases is also supporting the growth of the market. According
to the International Agency for Research on Cancer, in 2018, there were 18.1
million new cases and 9.5 million cancer-related deaths worldwide. By 2040, the
number of new cancer cases per year is expected to rise to 29.5 million and the
number of cancer-related deaths to 16.4 million. Therapeutic monoclonal
antibodies are majorly used across oncology, neurobiology, autoimmunology, and
cardiology area. Thus growing prevalence of various chronic diseases coupled
with the increasing advancement in drug development is further projected to
boost the growth of the antibodies
market.
North
America is projected to gain significant growth over the forecast period and
this is attributed to the growing number of research and development programs
for exploring the properties of therapeutic antibodies. For instance, in
September 2020, Eli Lilly has reported the interim results from a
placebo-controlled trial of one such compound, cloned in quantity from an
antibody captured from the blood of a patient who recovered from COVID-19. In
June, the company began a trial delivering either a placebo or one of three
doses of the antibody, called LY-CoV555, to 452 patients.
Key Developments:
1. In December 2019, Mylan and
Biocon announced the launch of a new product under the monoclonal antibody
therapy category. The company introduced ‘Ogivri,’ a product that is a
biosimilar of trastuzumab
2. In September 2020, Roche
announced the launch of its Elecsys® Anti-SARS-CoV-2 S antibody test for
markets accepting the CE Mark. Roche has filed for Emergency Use Authorisation
(EUA) from the U.S. Food and Drug Administration (FDA)
3. In April 2020, Abbott announced
the launch of its third COVID-19 test, a lab-based serology blood test for the
detection of the antibody, IgG that identifies if a person has had the novel
coronavirus (COVID-19)
4. In May 2020, French diagnostics
specialist BioMérieux announced the launch of a new product that aims to detect
within 30 minutes the presence of antibodies in those exposed to the
coronavirus.
Comments
Post a Comment